Literature DB >> 6780364

Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects.

E D Janus, A M Nicoll, P R Turner, P Magill, B Lewis.   

Abstract

Autologous 131I-labelled very low density lipoprotein (VLDL) and 125I-labelled low density lipoprotein (LDL) were injected into seven normal subjects and into forty-three hyperlipidaemic patients, classified into groups on the basis of family studies and clinical findings, to quantitate VLDL and LDL apolipoprotein B kinetics. In normal subjects, mean VLDL-B peptide synthetic rate was 15 . 1 mg kg-1 day-1, mean LDL-B peptide synthetic rate 7 . 7 mg kg-1 day-1 and mean LDL-B fractional catabolic rate (FCR) 0 . 31 day-1. In heterozygous familial hypercholesterolaemia (n = 14) VLDL-B peptide production was normal in patients with normal triglyceride levels; in those with high triglyceride levels there was either VLDL overproduction or a catabolic defect. LDL-B peptide synthetic rates ranged from high normal to increased (8 . 5--18 . 0 mg kg-1 day-1) and LDL-B peptide FCR values were markedly reduced (0 . 14--0 . 28 day-1) confirming the presence of a defect in LDL catabolism but indicating over-production as well. In familial combined hyperlipidaemia (n = 11) VLDL-B peptide production ranged from normal to elevated (13 . 9--44 . 4 mg kg-1 day-1, mean 23 . 8 mg kg-1 day-1) correlating with the VLDl triglyceride level (i.e. with the phenotypic expression of the disorder). LDL-B peptide production ranged from high normal to markedly increased (8 . 9--19 . 5 mg kg-1 day-1, mean 12 . 2 mg kg-1 day-1) and correlated with LDL cholesterol levels (i.e. the phenotype), (r = +0 . 66, P < 0 . 05). Three patients with unclassified hypercholesterolaemia had increased LDL-B peptide synthetic rates. One patient with remnant hyperlipoproteinaemia (type III) had a high normal VLDL-B peptide synthetic rate, 17 . 3 mg kg-1 day-1, and a strikingly low FCR of VLDL-B. In familial hypertriglyceridaemia (three patients) there was a low VLDL-B peptide FCR. In unclassified hypertriglyceridaemia VLDL over-production was the finding in seven patients but four patients appeared to have catabolic defects only. Overall there were significant hyperbolic relationships between VLCL-B peptide FCR and VLDL-B peptide concentration (r = -0 . 78, P < 0 . 001, for the log/log relationship) and between LDL-B peptide FCR and LDL cholesterol (r = -0 . 88, P < 0 . 001 for the log/log relationship.)

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6780364     DOI: 10.1111/j.1365-2362.1980.tb02076.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  30 in total

1.  FABP4 plasma levels are increased in familial combined hyperlipidemia.

Authors:  Anna Cabré; Iolanda Lázaro; Montserrat Cofán; Estibaliz Jarauta; Núria Plana; Angel L Garcia-Otín; Juan F Ascaso; Raimón Ferré; Fernando Civeira; Emilio Ros; Lluís Masana
Journal:  J Lipid Res       Date:  2010-05       Impact factor: 5.922

Review 2.  Genetic influences on susceptibility to atherosclerosis in the young.

Authors:  P O Kwiterovich
Journal:  Bull N Y Acad Med       Date:  1989-12

3.  Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia.

Authors:  B Teng; A D Sniderman; A K Soutar; G R Thompson
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  Splanchnic metabolism of plasma apolipoprotein B: studies of artery-hepatic vein differences of mass and radiolabel in fasted human subjects.

Authors:  P R Turner; N E Miller; C Cortese; W Hazzard; J Coltart; B Lewis
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

5.  Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

Authors:  S Eisenberg; D Gavish; Y Oschry; M Fainaru; R J Deckelbaum
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

6.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 7.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

8.  Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.

Authors:  H N Ginsberg; N A Le; M P Short; R Ramakrishnan; R J Desnick
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

9.  Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia.

Authors:  B Angelin; K S Hershon; J D Brunzell
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

10.  Significance of low density lipoprotein production in the regulations of plasma cholesterol level in man.

Authors:  Y A Kesaniemi; S M Grundy
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.